Avid Bioservices Highlights New Bioassay Capabilities to Support Phase III and Commercial-Stage Development Programs

Avid Bioservices Highlights New Bioassay Capabilities to Support Phase III and 
Commercial-Stage Development Programs 
Bioassays to Evaluate Activity and Function for Monoclonal Antibodies
Developed, Qualified and Implemented for Lot Release and Stability
Testing; Enhanced Bioassay Development Expertise Now Available to
Avid's Clients 
TUSTIN, CA -- (Marketwired) -- 05/14/13 --  Avid Bioservices, Inc., a
wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today
announced that its recent success in qualifying an
antibody-dependent, cell-mediated cytotoxicity (ADCC) bioassay will
be highlighted in a poster presentation at IBC's 23rd International
Intensive Symposium Development, Validation and Maintenance of
Biological Assays Conference to be held in Seattle, Washington, May
14-16, 2013. Avid customized a novel nuclear factor of activated T
cells (NFAT) potency assay to evaluate and characterize monoclonal
antibodies and with extensive testing yielding positive results, has
implemented this as part of its standard portfolio of Quality Control
(QC) lot release and stability testing capabilities. The latest
bioassay success is another example of the variety of bioassays
developed at Avid to characterize the activity and potency of
therapeutic proteins, including monoclonal antibodies. 
The poster will be on display in the poster and exhibit hall, May
14-15, 2013 at the Grand Hyatt Seattle: 
"Customization, Scale-up and Qualification of an Antibody-dependent
Cell-mediated Cytotoxicity (ADCC) Bioassay" 
 Location: Poster Board
#7 
"This is an important milestone for Avid that allows us to offer
simple and robust bioassays that avoid much of the variability seen
with classical methods," said Connie Chang, director of Process
Science for Avid Bioservices. "This latest bioassay provides greater
sensitivity and improved reliability, allowing the client to evaluate
process changes more effectively than with traditional ADCC-based
bioassays. The assay performance has remained consistent throughout
the optimization, qualification and scale-up steps, and now serves as
a reliable bioassay to support lot release and stability testing for
Phase III clinical trials and commercialization of their well
characterized biologic."  
For additional information on IBC's Development, Validation and
Maintenance of Biological Assays Conference, please visit:
http://www.ibclifesciences.com/bioassays/overview.xml 
About Avid Bioservices
 Avid Bioservices provides a comprehensive
range of high quality cGMP manufacturing services for the
biotechnology and biopharmaceutical industries to support the
manufacture of cGMP clinical phase and commercial products. With over
15 years of experience producing monoclonal antibodies and
recombinant proteins in batch, fed-batch and perfusion modes, Avid's
services include GMP clinical and commercial product manufacturing,
purification, bulk packaging, final product filling, stability
testing and regulatory strategy, submission and support. The company
also provides a variety of process development activities, including
cell line optimization, cell culture and feed optimization,
analytical methods development and product characterization. For more
information about Avid, please visit www.avidbio.com. 
About Peregrine Pharmaceuticals
 Peregrine Pharmaceuticals, Inc. is a
biopharmaceutical company with a portfolio of innovative monoclonal
antibodies in clinical trials for the treatment of cancer and serious
viral infections. The company is pursuing multiple clinical programs
in cancer and infectious diseases with its lead product candidate
bavituximab and novel brain cancer agent Cotara(R). Peregrine also
has in-house cGMP manufacturing capabilities through its wholly-owned
subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides
development and biomanufacturing services for both Peregrine and
outside customers. Additional information about Peregrine can be
found at www.peregrineinc.com.  
Contact:
Chris Keenan
Kelly Pisarev Lord
(800) 987-8256
www.avidbio.com